Adcetris (brentuximab vedotin) / Takeda, Pfizer - LARVOL DELTA

Golidocitinib-based therapy in relapsed/refractory mycosis fungoides and Sézary syndrome: A real-world retrospective analysis (ASH 2025) - "Combination strategies predominated (n=9, 90%), with all combination regimens incorporating brentuximab vedotin (BV; 1.8 mg/kg IV q3wk). This pioneering real-world study demonstrates the favorable clinical efficacy and safety of Go-based regimens in pretreated MF/SS patients. Subsequent prospective trials are warranted to further explore combination strategies."

Real-world • Real-world evidence • Retrospective data • Cutaneous T-cell Lymphoma • Cytomegalovirus Infection • Dermatology • Hematological Malignancies • Infectious Disease • Lymphoma • Mycosis Fungoides • Oncology • Peripheral T-cell Lymphoma • Sezary Syndrome • Skin Cancer • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • CD4 • IFNG

GMP-compliant generation, expansion, and a preliminary safety evaluation of CMV-specific t cells using a closed system for post-transplant viral control (ASH 2025) - "His prior treatments included ABVD, DHAP, ICE, GVD, brentuximab vedotin (BV), autologous hematopoietic stem cell transplantation, and pembrolizumab, which led to complete remission...The post-transplant course was complicated by chronic graft-versus-host disease (overlap subtype), presenting with grade 3 skin and grade 2 oral involvement, which was managed with prednisone and tacrolimus. In early 2025, the patient developed CMV reactivation with a high viral load (>200,000 copies/mL) that proved refractory to ganciclovir, which was discontinued due to hematologic toxicity and the detection of viral resistance associated with an M460V mutation...These findings support further investigation of CMV-specific T cell therapy as a valuable adjunct in managing opportunistic infections in immunocompromised hosts. Funding: Ministry of Health of Brazil, SIPAR (NUP) 25000.156425/2023-06"

Clinical • Post-transplantation • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Classical Hodgkin Lymphoma • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Transplantation • IFNG • IL2 • IL7

Real-world efficacy and safety of pomalidomide-rituximab-based combination therapy in newly diagnosed extranodal diffuse large B-cell lymphoma (ASH 2025) - "Introduction The R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone) has been established as the standard first-line therapy for diffuse large B-cell lymphoma (DLBCL) in clinical practice...Pomalidomide, a third-generation immunomodulatory agent, exhibits more potent immunomodulatory effects compared to lenalidomide...Pomalidomide-rituximab was combined with CHOP-like regimens (n = 10), bendamustine (n = 1), brentuximab vedotin (n = 1), or BTK inhibitors (n = 2)...Grade 3-4 non-hematological AEs occurred in four patients, including one with hyponatremia and three with infections. Conclusion This real-world analysis demonstrated that the pomalidomide-rituximab-based combination therapy had promising efficacy, with a high ORR of 92.9%, in treatment-naïve DLBCL patients with extranodal disease, and exhibited acceptable hematological toxicity."

Clinical • Combination therapy • Real-world • Real-world effectiveness • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Gastrointestinal Disorder • Heart Failure • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Rare Diseases • Thrombocytopenia • CD5 • TP53

Efficacy of BV-R2 therapy in relapsed/refractory DLBCL: A single centre preliminary retrospective analysis (ASH 2025) - "The phase 3 ECHELON-3 study demonstrated significant overall survival (OS) and progression-free survival (PFS) benefits with brentuximab vedotin plus lenalidomide and rituximab (BV-R2) compared to lenalidomide-rituximab (R2) in TIE R/R DLBCL. The BV-R2 regimen demonstrates encouraging efficacy and a tolerable safety profile in this initial real-world cohort of patients with TIE R/R DLBCL. Longer follow-up and a larger patient cohort are needed to validate these preliminary findings."

Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Interstitial Lung Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Pneumonia • Respiratory Diseases

Safety and effectiveness of brentuximab vedotin in Chinese patients with CD30-positive lymphomas: A multicenter real-world analysis (ASH 2025) - "Post-BV failure, chidamide predominated as salvage therapy in PTCL, while PD-1 inhibitors or azacitidine were preferentially selected in cHL. Conclusions In this Chinese real-world cohort, BV-based regimens produced high ORR and CR rates in both treatment-naïve and R/R CD30-positive lymphomas, with manageable toxicity. These data support BV as an effective backbone across diverse CD30-positive lymphomas in routine Chinese practice."

Clinical • IO biomarker • Real-world • Real-world evidence • B Cell Lymphoma • Classical Hodgkin Lymphoma • Cutaneous T-cell Lymphoma • Diffuse Large B Cell Lymphoma • Extranodal Natural Killer/T-cell Lymphoma • Febrile Neutropenia • Hodgkin Lymphoma • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Natural Killer/T-cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • Primary Mediastinal Large B-Cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • TNFRSF8

Updated real-world outcomes with brentuximab vedotin in lymphoma patients: A multicenter, retrospective study from China (ASH 2025) - "Our findings further solidify the role of BV as an efficacious and generally well-tolerated treatment for Chinese patients with CD30-positive lymphoma. Besides, the results underscore its potential not only in first-line therapy but also as a bridge therapy and consolidation to SCT, thereby highlighting its utility in various stages of lymphoma treatment."

Real-world • Real-world evidence • Retrospective data • Classical Hodgkin Lymphoma • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Leukopenia • Lymphoma • Non-Hodgkin’s Lymphoma • TNFRSF8

Patterns of presentation, treatment, and survival in primary mediastinal B cell lymphoma: A colombian retrospective cohort (ASH 2025) - "R-CHOP protocol was the most common induction regimen (58.8%, n =10) followed by ABVD (23.5%, n=4), Bortezomib combined with Rituximab-Mitoxantrone (11.7%, n=2) and ICE (5,8%, n=1)...Likewise, there was a significant lack of access to Nivolumab and Brentuximab Vedotin, which has shown promising early efficacy in patients with R/R PMBCL as has been described in large clinical trials such as CheckMate 436 (Zinzani et al., 2019)... This small single center retrospective cohort study is one of the first to be conducted regarding PMBL in Latin America and to our knowledge first conducted in Colombia. Our findings regarding survival suggest efficient disease control, however with a high risk for late relapse beyond five years. In that sense, larger local real world studies are needed and it is crucial to emphasize on diagnosis and treatment strategies used in this region in order to optimize clinical outcomes in resource limited settings."

Retrospective data • B Cell Lymphoma • Cardiovascular • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma • Respiratory Diseases • CD20 • MME • TNFRSF8

Synergistic Remission of refractory cutaneous T-cell lymphoma by linperlisib plus venetoclax via targeting the PI3K/AKT/CREB-BCL-2/MCL-1 signaling axis. (ASH 2025) - " We report a 67-year-old woman with multiply relapsed pcALCL refractory to CHOP, CHOP plus brentuximab vedotin (BV), and three courses of total skin electron beam therapy (TSEBT), who subsequently initiated combination therapy with linperlisib (PI3Kδ inhibitor) and venetoclax (BCL-2 inhibitor). In this case, dual PI3Kδ and BCL-2 blockade achieved durable remission after failure of all conventional therapies. Linperlisib suppresses BCL-2/MCL-1 expression by inhibiting the PI3K/AKT/CREB axis, synergizing with venetoclax to overcome resistance. This combination represents a novel therapeutic strategy for achieving durable remission in relapsed pcALCL."

Clinical • IO biomarker • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • BCL2 • MCL1 • PIK3CD • TNFRSF8

A tale of two lymphomas: A rare case of transformative post-transplant lymphoproliferative disorder (ASH 2025) - "Our 61-year-old patient underwent a living-unrelated renal transplant in 2014 for focal segmental glomerulosclerosis and was maintained on mycophenolate mofetil (MMF) and cyclosporine (CsA)...MMF was discontinued, and he received four weekly doses of rituximab (375 mg/m²), achieving complete remission (CR) and was consolidated with four additional Rituximab doses by Jan 2024...After improvement of liver and kidney function, therapy was escalated to brentuximab vedotin (BV) with cyclophosphamide, doxorubicin, and prednisone (CHP), given his CD30 expression...After detailed goals-of-care discussions, he and the care team elected to proceed with additional therapy with EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), since he already received azacitidine, romidepsin, and BV-CHP...His care underscores the importance of multidisciplinary collaboration, patient-centered decision-making, and longitudinal follow-up. He has been referred to our..."

Clinical • IO biomarker • Post-transplantation • Bone Marrow Transplantation • Chronic Kidney Disease • Epstein-Barr Virus Infections • Febrile Neutropenia • Focal Segmental Glomerulosclerosis • Follicular Lymphoma • Glomerulonephritis • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Hepatology • Immunology • Infectious Disease • Liver Failure • Lymphoma • Nephrology • Peripheral T-cell Lymphoma • Rare Diseases • T Cell Non-Hodgkin Lymphoma • Transplantation • BCL6 • CD21 • CD4 • CD5 • CD7 • ICOS • JAK1 • PD-1 • RHOA • TET2 • TNFRSF8

Efficacy and safety of brentuximab vedotin versus standard therapy for cutaneous T-cell lymphoma: A systematic review and meta-analysis (ASH 2025) - "Although the CI excluded the null value, the p-value remained above the conventional threshold for significance, most likely due to the limited number of included studies and small sample size. Our findings suggest a potential treatment benefit; however, they should be interpreted cautiously. Thus, we suggest further large-scale trials to validate these efficacy outcomes and also identify predictors of PN and develop strategies to mitigate this adverse effect."

Retrospective data • Review • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • T Cell Non-Hodgkin Lymphoma • TNFRSF8

Chidamide in combination with brentuximab vedotin for CD30+ peripheral T-cell lymphoma in patients ineligible for chemotherapy: a prospective phase II study (ASH 2025) - P=N/A | "With traditional anthracycline-based chemotherapy regimens such as CHOP (cyclophosphamide + doxorubicin + vincristine + prednisolone), approximately 70% of PTCL patients develop refractory or relapsed disease. This preliminary study demonstrates the favorable efficacy and significantly lower hematological toxicities of the BvC regimen in CD30-positive PTCL patients, offering a promising therapeutic option for this challenging population. Further updated clinical data will be shared as the study progresses."

Clinical • Combination therapy • P2 data • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • TNFRSF8

A phase I dose-finding study of mogamulizumab in combination with brentuximab vedotin in previously treated mycosis fungoides and Sézary syndrome (ASH 2025) - P1 | "Enrollment is ongoing and additional pt data will be presented at the meeting. Acknowledgements: Drug support and trial funding for this study were provided by Pfizer and Kyowa Kirin, Inc."

Combination therapy • P1 data • Cutaneous T-cell Lymphoma • Dermatology • Musculoskeletal Pain • Mycosis Fungoides • Oncology • Sezary Syndrome • CCR4 • TNFRSF8

Real world outcome of nodal T cell non-Hodgkin lymphoma from hematology cancer consortium registry in India (ASH 2025) - "Azacytidine with CHP was used in 2 patients, and Brentuximab with CHP was used in 1 patient. Our data reflects the poor outcome of nodal T-NHL with current available therapy. Modes of staging, choice of initial protocol, and consolidation with SCT differed from centre to centre based on practical issues like finance and patient/physician preference. Data loss due to lost follow-up (42%) and short median follow-up duration are the major drawbacks in this registry analysis."

Clinical • Real-world • Real-world evidence • Febrile Neutropenia • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Palliative care • T Cell Non-Hodgkin Lymphoma • ALK

Continued risk of relapse in peripheral T-cell lymphoma even in patients who achieved complete response after initial therapy (ASH 2025) - "Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) has been the standard initial therapy for PTCL; however, clinical outcomes remain suboptimal. The introduction of brentuximab vedotin (BV)-CHP has improved survival in CD30-positive PTCL patients (pts) and has become the standard therapy for this subgroup...Of the 33 pts who subsequently received salvage therapy, 22 received at least one novel agent (e.g., BV, romidepsin, pralatrexate, tucidinostat), and 19 received conventional chemotherapy... PTCL pts who achieved CR after initial therapy demonstrated favorable long-term survival. However, more than half experienced relapse, with no clear plateau in relapse risk. This finding indicates a continued risk of relapse and highlights the need for long-term monitoring."

Clinical • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK • TNFRSF8

Hematopoietic stem cell transplantation in T-cell lymphomas: A promising strategy challenging poor prognosis (ASH 2025) - "Four (10%) patients received brentuximab...Myeloablative conditioning was used in 92.5%, primarily PEAM in autologous, and fludarabine/busulfan-based regimens in allogenic settings... HSCT proved to be a viable therapeutic option, particularly in advanced-stage disease, challenging the historically poor outcomes associated with TCL. HSCT was successfully performed as consolidation therapy and in R/R cases, resulting in improved outcomes. The increased risk of progression in R/R group reinforces the value of HSCT as consolidation in CR1."

Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Lymphoblastic Lymphoma • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Transplantation • ALK • TNFRSF8

Combination of brentuximab vedotin and nivolumab in the management of Hodgkin lymphoma: A systematic review and meta-analysis (ASH 2025) - "Conclusion This meta-analysis suggests that the combination of Brentuximab Vedotin and Nivolumab may improve survival and increase the progression-free interval in patients with advanced, relapsed, or refractory Hodgkin's lymphoma, with an acceptable safety profile. Future high-quality trials with larger patient populations are needed to consolidate these findings."

Retrospective data • Review • Hematological Malignancies • Hodgkin Lymphoma • Leukopenia • Lymphoma • Neutropenia

Fulminant immune checkpoint inhibitor encephalitis associated with nivolumab: Case report and review of the literature (ASH 2025) - "Case Presentation: Within 24 hours of initiating nivolumab combined with brentuximab (an antibody-drug conjugate), a White male in his 70s with recurrent Hodgkin lymphoma and history of cutaneous T-cell lymphoma presented with altered mental status, status epilepticus, and abnormal signal in the bilateral temporal lobes on brain magnetic resonance imaging (MRI)...Following multidisciplinary consultation, the patient was ultimately diagnosed with ICI-encephalitis and begun on empiric treatment with intravenous methylprednisolone dosed 1 g/day for 5 days, followed by 5 days of intravenous immunoglobulin (IVIG)... This case serves as a safety signal for fulminant irAE following nivolumab administration. According to available literature, this represents the most rapidly-presenting case of fulminant irAE following administration of an ICI."

Case report • Checkpoint inhibition • Clinical • Review • CNS Disorders • Cutaneous T-cell Lymphoma • Epilepsy • Genetic Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Oncology • Skin Cancer • T Cell Non-Hodgkin Lymphoma

Preservation of gonadal function following chemotherapy protocols with acvd and acvd-BV in adults diagnosed with advanced-stage Hodgkin lymphoma: A single center experience. (ASH 2025) - "ACVD (Adriamycin 25 mg/m², Cyclophosphamide 400 mg/m², Vinblastine 6 mg/m² (max 10 mg) and Dacarbazine 375 mg/m²) is a modified chemotherapy regimen from ABVD given IV on day 1 and day 15 and repeated every 28 days for 6 cycles, replacing bleomycin with low dose cyclophosphamide to further optimize efficacy and reduce pulmonary and gonadal toxicity. Brentuximab vedotin is added to ACVD (ACVD-BV) in those cases of positive PET following 2 cycles of ACVD...Sperm banking was performed for 18/34 (53%) males before starting chemotherapy, and only 3/22 (13.617%) females received leuprorelin (GnRH agonist) during the chemotherapy... This study shows a favorable advantage of ACVD /ACVD-BV chemotherapy in treating advanced-stage HL where majority of cases gained their gonadal functions. However, limitations include retrospective design, missing baseline gonadal function evaluation, particularly semen analyses, and inconsistent hormone level documentation...."

Clinical • Metastases • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Real-world, multicenter study of brentuximab vedotin-based regimens in Chinese patients with relapsed/refractory Hodgkin lymphoma (ASH 2025) - P4 | "The BV-containing treatment mainly included AVD, ICE, bendamustine and PD-1 monoclonal antibodies. BV-based therapeutic regimens demonstrated superior efficacy and an acceptable safety profile in Chinese patients with r/r cHL, potentially establishing them as a preferred therapeutic option for this patient population."

Clinical • Real-world • Real-world evidence • Classical Hodgkin Lymphoma • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia • Pneumonia • Respiratory Diseases • Thrombocytopenia

Efficacy and safety of nivolumab-based therapies in first-line and Relapsed/Refractory Hodgkin lymphoma (ASH 2025) - "Combination regimens involving nivolumab with agents such as brentuximab vedotin (BV), AVD (adriamycin, vinblastine, dacarbazine) combination chemotherapy, and novel immunomodulators have shown promising activity. In relapsed or refractory CHL, nivolumab-based regimens are highly effective, producing durable responses and favorable survival outcomes, especially when combined with chemotherapy or antibody-drug conjugates such as BV. Although AEs are more common in multi-agent regimens, the safety profile remains acceptable. Nivolumab's role as a salvage or consolidation therapy is supported, given its relatively lower efficacy in the first-line therapeutic context."

Clinical • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

High transplant conversion rates with gemcitabine, dexamethasone and carboplatin (GDP)-based therapy in Relapsed/Refractory lymphoma: A real-world experience (ASH 2025) - "G-CSF and Plerixafor-mobilized peripheral blood stem cell were used in all patients...Eligible patients received agents like Rituximab, Brentuximab, and Nivolumab with additional cost per cycle...The regimen's daycare feasibility and reduced hospitalization needs offer significant quality-of-life and economic advantages. Substituting Carboplatin for Cisplatin further enhances administration convenience."

Clinical • Real-world • Real-world evidence • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • Transplantation

Safety and effectiveness of brentuximab vedotin in Chinese adult patients with classical Hodgkin's lymphoma: Results from a multicenter, prospective, observational, real-world study (ASH 2025) - P | "This is the largest real-world study of brentuximab vedotin in Asian patients with classical Hodgkin lymphoma. No new safety signals were identified relative to clinical trials. Outcomes with BV were similar across Arbor stages in newly diagnosed disease, yet efficacy remains suboptimal in elderly and RR populations, underscoring the need for optimizing BV-based therapeutic protocols."

Clinical • Observational data • Real-world • Real-world evidence • Classical Hodgkin Lymphoma • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Respiratory Diseases • TNFRSF8

Checkpoint inhibitors improve progression free survival after autologous transplant despite poorer pre-transplant response (ASH 2025) - "Introduction The checkpoint inhibitors (CI) nivolumab and pembrolizumab which target PD1 are established treatments for relapsed/refractory classic Hodgkin Lymphoma (cHL)...44 received brentuximab vedotin (BV)...All patients were conditioned with LEAM (lomustine, etoposide, cytarabine, melphalan)...CI treatment prior to ASCT may alter cHL disease biology leading to increased sensitization to subsequent high dose cytotoxic chemotherapy although more exploratory data assessing the mechanism is needed. We are planning a multi-centre analysis to investigate further."

Checkpoint inhibition • Pre-transplantation • Cardiovascular • Classical Hodgkin Lymphoma • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Metabolic Disorders • Oncology • Pneumonia • Transplantation

Treatment practices and outcomes of advanced stage classical Hodgkin lymphoma in India: An analysis from the hematology cancer consortium (ASH 2025) - "Other regimens included BEACOPP (n=39; 5.5%), platinum-based protocols (n=8; 1.1%), and regimens with Brentuximab Vedotin (n=3; 0.4%) or Nivolumab (n=7; 1.0%)...Bleomycin toxicity was reported in 48 (7%) patients and 4 patients succumbed to the same...iPET response was the strongest predictor of event-free survival, outperforming traditional prognostic markers like the IPS score. Combining iPET and IPS can be further used to stratify risk, though this requires validation in prospective cohorts."

Metastases • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Hodgkin lymphoma in a patient with Hemophilia A on emicizumab prophylaxis: A case report (ASH 2025) - "He completed five cycles of chemotherapy with brentuximab, doxorubicin, etoposide, prednisone, cyclophosphamide and vincristine. As emicizumab is intended for long term maintenance therapy, it is critical to report any significant adverse events. This case further suggests that continued use of emicizumab during cancer-directed therapies is safe and effective for patients with hemophilia A."

Case report • Clinical • Classical Hodgkin Lymphoma • Hematological Malignancies • Hemophilia • Hemophilia A • Hemophilia B • Hodgkin Lymphoma • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Rare Diseases • Thrombocytopenia